The advent of checkpoint inhibitors has revolutionized the systemic treatment of many malignancies, including renal cell carcinoma (RCC), and in clinical trials, a variety of PD-1, PD-L1, and CTLA-4 inhibitors have been shown to respond to patients and improve patient survival [23]. Here, CD274 is linked to hereditary clear cell renal cell carcinoma.